Results 231 to 240 of about 86,221 (308)

Urinary Calcium and Phosphorus Excretion in Vitamin D‐Sufficient Preterm Infants: Establishing Age‐Specific Normative Data

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim This study evaluated urinary calcium (Ca) and phosphorus (P) excretion in very low birth weight infants ( < 1500 g, VLBW) without severe morbidity, treated with methylxanthines. Methods Eighty‐one VLBW infants were analysed. Urinary Ca and P and their creatinine ratios were measured biweekly until day 56.
Tomas Matejek   +5 more
wiley   +1 more source

Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Features of clinically significant portal hypertension (CSPH) in patients with autoimmune hepatitis indicate a substantial risk for decompensation and impaired transplant‐free survival. Non‐invasive risk prediction based on liver stiffness measurement ≥ 15 kPa and/or thrombocytopenia (< 150 G/L) serves as a valuable surrogate to identify patients at ...
Lukas Burghart   +10 more
wiley   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu   +9 more
wiley   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas   +18 more
wiley   +1 more source

Unstable Recompensation: An Intermediate Subtype in Patients With HBV‐Related Decompensated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Recompensation is a heterogeneous and dynamic state in HBV‐related decompensated cirrhosis; The prognosis for patients with unstable recompensation was found to be worse compared to those with stable recompensation, but still better than patients without recompensation; Subclassification of recompensation has significant implications for prognosis and ...
Shuai Xia   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy